Australia markets closed

Mainz Biomed N.V. (MYNZ)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.8705-0.0095 (-1.08%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.8800
Open0.9000
Bid0.8568 x 100
Ask0.9223 x 100
Day's range0.8700 - 0.9049
52-week range0.8500 - 6.0000
Volume66,373
Avg. volume83,696
Market cap19.052M
Beta (5Y monthly)0.24
PE ratio (TTM)N/A
EPS (TTM)-1.6200
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • GlobeNewswire

    Mainz Biomed Reports Full Year 2023 Financial Results

    ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 MillionBERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023. “This past fiscal year represented an important period of progress for the C

  • GlobeNewswire

    Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

    BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO DOC! event, informing about colorectal cancer, cutting-edge research, new treatment modalities, and holistic therapeutic approaches. This event will take place on March 20, 2024, in Berlin, Germany, aligning with the Colorectal Cancer Awareness Month.

  • GlobeNewswire

    Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

    BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024. Designed for pharmacists, physicians, and healthcare professionals, this online training session ai